Palettes of vaccines and immunostimulatory monoclonal antibodies for combination
I Melero, I Martinez-Forero, J Dubrot, N Suarez… - Clinical Cancer …, 2009 - AACR
Clinical Cancer Research, 2009•AACR
Various monoclonal antibodies (mAb) target immune system molecules to enhance
immunity by costimulating T cells (ie, CD137, OX40, CD40, GITR) or interfering in
coinhibitory signals (ie, CTLA-4, PD-1). These powerful agents can be guided by cancer
vaccines to enhance immunity against tumor but not self tissues. Clinically powerful
therapeutic synergies are at hand.
immunity by costimulating T cells (ie, CD137, OX40, CD40, GITR) or interfering in
coinhibitory signals (ie, CTLA-4, PD-1). These powerful agents can be guided by cancer
vaccines to enhance immunity against tumor but not self tissues. Clinically powerful
therapeutic synergies are at hand.
Abstract
Various monoclonal antibodies (mAb) target immune system molecules to enhance immunity by costimulating T cells (i.e., CD137, OX40, CD40, GITR) or interfering in coinhibitory signals (i.e., CTLA-4, PD-1). These powerful agents can be guided by cancer vaccines to enhance immunity against tumor but not self tissues. Clinically powerful therapeutic synergies are at hand.
AACR